Shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $12.86.
Separately, JPMorgan Chase & Co. lowered their target price on shares of Kodiak Sciences from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, April 4th.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the stock. Point72 Middle East FZE acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $27,000. UBS Group AG lifted its stake in shares of Kodiak Sciences by 26,200.0% during the third quarter. UBS Group AG now owns 6,575 shares of the company’s stock valued at $51,000 after acquiring an additional 6,550 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Kodiak Sciences during the third quarter valued at $55,000. Royal Bank of Canada lifted its stake in Kodiak Sciences by 89.0% in the third quarter. Royal Bank of Canada now owns 7,592 shares of the company’s stock valued at $59,000 after buying an additional 3,575 shares during the period. Finally, Ensign Peak Advisors Inc lifted its stake in Kodiak Sciences by 64.4% in the third quarter. Ensign Peak Advisors Inc now owns 9,570 shares of the company’s stock valued at $74,000 after buying an additional 3,750 shares during the period. 80.02% of the stock is owned by institutional investors.
Kodiak Sciences Stock Up 0.5 %
Kodiak Sciences Company Profile
Kodiak Sciences, Inc is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD.
- Get a free copy of the StockNews.com research report on Kodiak Sciences (KOD)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.